You are about to leave a GSK website

Third party content disclaimers

 

You are about to leave a GSK website. By clicking this link, you will be taken to a website that is independently operated and not managed by GSK. The website you are linking to is not controlled or endorsed by GSK and GSK assumes no responsibility for the content on the website. If you wish to proceed, click "OK". If you do not wish to leave this website, click “CANCEL”.

OK

CANCEL

Product menu

Guideline-defined asthma control

According to the Global Initiative for Asthma (GINA), the long-term goals of asthma management are:1

  • To achieve good control of symptoms and maintain normal activity levels
  • To minimise the risk of asthma-related death, exacerbations, persistent airflow limitation, and side effects

Asthma control is required to realise both of these goals – but what does this mean for patients?

Based on GINA guidelines, asthma control can be defined as:1

A good night’s sleep

Patients with well-controlled asthma have not woken up at night due to symptoms in the last 4 weeks

Freedom of activity  

Patients with well-controlled asthma have not experienced activity limitations in the last 4 weeks

Minimal need for rescue inhaler 

Patients with well-controlled asthma use SABA no more than twice a week 

Other benefits include few daytime symptoms and reduced risk of exacerbations vs poorly controlled asthma.1

The Asthma Control Test
The Asthma Control Test

For patients, the clinically-validated Asthma Control Test (ACT) is a useful way for your patients to better understand and improve their perception of asthma control. 

The test is based on the four GINA indicators above, but also includes the patient’s perception of asthma control.2,3

Shortness of 
breath due to asthma

Overuse of 
rescue medicine

Night time waking 
due to asthma

Effect of asthma on 
activity levels

Patient’s perception 
of asthma control

All assessment questions refer to the previous 4 weeks and are answered with a score of 1 to 5.2,3

The composite score indicates the level of asthma control:

  • 5–15 is considered very poorly controlled
  • 15–20 is considered poorly controlled
  • 20–25 is considered well controlled

An improvement of 3 points is the minimal clinically important difference.3

The GINA guidelines define well controlled as no symptoms.1

VISIT THE ACT WEBSITE

Discover more about Seretide

Device

Sustained asthma control

Help your patients achieve and maintain asthma control with Seretide4

FIND OUT MORE
Value of Seretide

Symptoms and exacerbations

What does sustained asthma control mean for the frequency of symptoms and exacerbations?

FIND OUT MORE
safety

Safety

Uncover the safety profile of Seretide in adult patients

FIND OUT MORE

 

Abbreviations

ACT, Asthma Control Test; GINA, Global Initiative for Asthma; SABA, short-acting β2-agonist.

Safety Information5

Seretide is contraindicated in patients with a history of hypersensitivity to any of the ingredients.

Increasing use of short-acting bronchodilators to relieve symptoms indicates deterioration of control and patients should be reviewed by a physician.

Common adverse events include candidiasis of mouth and throat, pneumonia (in COPD patients), hoarseness/dysphonia, muscle cramps, arthralgia.

References

  1. GINA. Global strategy for asthma management and prevention, 2021. Available at:www.ginasthma.org. Accessed June 2021.
  2. Asthma Control Test. Available at: http://www.asthmacontroltest.com. Accessed June 2021.
  3. Schatz M, et al. J Allergy Clin Immunol 2009;124:719–723.e1.
  4. Bateman ED, et al. Am J Respir Crit Care Med 2004;170:836–844.
  5. Seretide Prescribing Information, Version 05.

Trade marks are owned by or licensed to the GSK group of companies.

PM-MY-FPS-WCNT-210004 01/22